Astrana Health, Inc. Hits New 52-Week High of USD 47.09

Astrana Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 47.09 on June 30, 2026. This achievement underscores the company's strong performance in the miscellaneous industry, where it has demonstrated a notable one-year return of 17.85%, although slightly below the S&P 500's performance of 20.86%. With a market capitalization of USD 1,362 million, Astrana Health is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 58.00, reflecting its growth potential. The company maintains a healthy financial profile, being net-debt free and showcasing a debt-to-equity ratio of 0.79. Its return on equity (ROE) is reported at 3.02%, indicating efficient management. Astrana Health has also shown impressive growth metrics, with net sales increasing at an annual rate of 35.87% and net profit soaring by 140.64%. The company reported its highest operating cash flow at USD 166.03 million and cash equivalents at USD 907.97 million, further solidifying its financial stability. The stock's performance has outpaced the market, generating a return of 82.09% over the past year.